On July 7, 2025, Immunic, Inc. announced plans to grant 35 million stock appreciation rights (SARs) to employees and executives, with plans to settle these in shares pending stockholder approval; the exercise price for these rights is set at $0.77. Of these, 22 million are specifically for executive officers, allowing for cash settlement but aiming for stock settlement instead.